UPC_CFI_195/2024
BROWN MUSHROOMS FOR COMMERCIAL PRODUCTION
Amycel LLC obtained a preliminary injunction from The Hague Local Division against a defendant (GDPR-redacted) prohibiting direct infringement of EP 1 993 350 B2, a patent covering a hybrid Agaricus bisporus (brown mushroom) strain, across the Netherlands, Germany, France, and Italy. The court held the mushroom strain was not excluded from patentability under Art. 53(b) EPC and found a prima facie case of infringement by the defendant's Cayene mushroom strain. The defendant was ordered to deliver up infringing strains, disclose customer information, pay EUR 11,000 in interim costs, and provide EUR 200,000 security to Amycel.
Mushroom strain (Agaricus bisporus hybrid BR06/Cayene) is not excluded from patentability under Art. 53(b) EPC
KlägerRechtsgrundlage: Art. 53(b) EPCHinweis: The court found a prima facie case that the mushroom strain patent does not fall within the biological-exclusion exception, supporting patentability.
Prima facie case of direct infringement of EP 1 993 350 B2 by the Cayene mushroom strain
KlägerRechtsgrundlage: Art. 25(a) UPCA; Art. 63(1) UPCAHinweis: The court accepted Amycel's showing that defendant's commercialisation of Cayene in NL, DE, FR, IT fell within the patent claims.
Security of EUR 200,000 required as condition for enforcing provisional measures
BeklagterRechtsgrundlage: R. 211.5 RoPHinweis: Defendant's request for security was granted because Amycel did not object, and the court used it to set the case value.
Requested case value of EUR 500,000 for determining recoverable-costs ceiling
KlägerRechtsgrundlage: R. 211.5 RoPBegründung: Court found the EUR 500,000 figure insufficiently substantiated and instead used the EUR 200,000 security amount as a proxy for case value.
Weitere Fälle zu diesem Grundsatz ansehen.